LLY

by Jacob Braun
Contributor since 2021 / 1648 Followers

2 years ago

Summary: Eli Lilly currently has a forward P/E of over 45x. This high valuation is

by Acutel
Contributor since 2013 / 867 Followers

2 years ago

Summary: LLY is one of the best performing pharmaceutical stocks in 2022 and has reached

by Dividend Appreciator
Contributor since 2014 / 2375 Followers

2 years ago

Summary: Eli Lilly and Company is fairly new to the dividend growth club. The company

by Jonathan Weber
Contributor since 2014 / 45852 Followers

2 years ago

Summary: Eli Lilly is a quality company with a strong product lineup. Its exposure to

by Alexander Ebbinghouse
Contributor since 2021 / 563 Followers

2 years ago

Summary: Eli Lilly stock has defied the bear market of 2022 and is now up

by Lane Simonian
Contributor since 2015 / 2238 Followers

3 years ago

Summary: Anti-amyloid drugs only modestly slow down the progression of Alzheimer’s disease in APOE4 carriers

by Edmund Ingham
Contributor since 2018 / 8244 Followers

3 years ago

Summary: Eli Lilly’s share price performance over the past 5 years is +290%. The rest

by Daniel Schönberger
Contributor since 2016 / 9997 Followers

3 years ago

Summary: Eli Lilly has several products with growth potential and especially recently introduced Mounjaro could

by Nathan Aisenstadt
Contributor since 2021 / 2528 Followers

3 years ago

Summary: Eli Lilly’s net income was $952.5 million in Q2 2022, down 31.5% year-over-year. Eli